These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 21778331)

  • 1. Characterization of new founder Alu-mediated rearrangements in MSH2 gene associated with a Lynch syndrome phenotype.
    Pérez-Cabornero L; Borrás Flores E; Infante Sanz M; Velasco Sampedro E; Acedo Becares A; Lastra Aras E; Cuevas González J; Pineda Riu M; Ramón y Cajal Asensio T; Capellá Munar G; Miner Pino C; Durán Domínguez M
    Cancer Prev Res (Phila); 2011 Oct; 4(10):1546-55. PubMed ID: 21778331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frequency of rearrangements in Lynch syndrome cases associated with MSH2: characterization of a new deletion involving both EPCAM and the 5' part of MSH2.
    Pérez-Cabornero L; Infante Sanz M; Velasco Sampedro E; Lastra Aras E; Acedo Becares A; Miner Pino C; Durán Domínguez M
    Cancer Prev Res (Phila); 2011 Oct; 4(10):1556-62. PubMed ID: 21791569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Germline novel MSH2 deletions and a founder MSH2 deletion associated with anticipation effects in HNPCC.
    Stella A; Surdo NC; Lastella P; Barana D; Oliani C; Tibiletti MG; Viel A; Natale C; Piepoli A; Marra G; Guanti G
    Clin Genet; 2007 Feb; 71(2):130-9. PubMed ID: 17250661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High frequency of exon deletions and putative founder effects in French Canadian Lynch syndrome families.
    Chong G; Jarry J; Marcus V; Thiffault I; Winocour S; Monczak Y; Drouin R; Latreille J; Australie K; Bapat B; Gordon PH; Giguère Y; Gologan A; Galiatsatos P; Jass JR; Wong N; Zaor S; Palma L; Kasprzak L; Tischkowitz M; Foulkes WD
    Hum Mutat; 2009 Aug; 30(8):E797-812. PubMed ID: 19459153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Founder effect of a pathogenic MSH2 mutation identified in Spanish families with Lynch syndrome.
    Menéndez M; Castellví-Bel S; Pineda M; de Cid R; Muñoz J; González S; Teulé A; Balaguer F; Ramón y Cajal T; Reñé JM; Blanco I; Castells A; Capellà G
    Clin Genet; 2010 Aug; 78(2):186-90. PubMed ID: 20095990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spectrum of MLH1 and MSH2 mutations in Chilean families with suspected Lynch syndrome.
    Alvarez K; Hurtado C; Hevia MA; Wielandt AM; de la Fuente M; Church J; Carvallo P; López-Köstner F
    Dis Colon Rectum; 2010 Apr; 53(4):450-9. PubMed ID: 20305446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Origins and prevalence of the American Founder Mutation of MSH2.
    Clendenning M; Baze ME; Sun S; Walsh K; Liyanarachchi S; Fix D; Schunemann V; Comeras I; Deacon M; Lynch JF; Gong G; Thomas BC; Thibodeau SN; Lynch HT; Hampel H; de la Chapelle A
    Cancer Res; 2008 Apr; 68(7):2145-53. PubMed ID: 18381419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deletions removing the last exon of TACSTD1 constitute a distinct class of mutations predisposing to Lynch syndrome.
    Kovacs ME; Papp J; Szentirmay Z; Otto S; Olah E
    Hum Mutat; 2009 Feb; 30(2):197-203. PubMed ID: 19177550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genomic rearrangements in MSH2, MLH1 or MSH6 are rare in HNPCC patients carrying point mutations.
    Pistorius S; Görgens H; Plaschke J; Hoehl R; Krüger S; Engel C; Saeger HD; Schackert HK
    Cancer Lett; 2007 Apr; 248(1):89-95. PubMed ID: 16837128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Germ line MLH1 and MSH2 mutations in Taiwanese Lynch syndrome families: characterization of a founder genomic mutation in the MLH1 gene.
    Tang R; Hsiung C; Wang JY; Lai CH; Chien HT; Chiu LL; Liu CT; Chen HH; Wang HM; Chen SX; Hsieh LL;
    Clin Genet; 2009 Apr; 75(4):334-45. PubMed ID: 19419416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distinct patterns of germ-line deletions in MLH1 and MSH2: the implication of Alu repetitive element in the genetic etiology of Lynch syndrome (HNPCC).
    Li L; McVety S; Younan R; Liang P; Du Sart D; Gordon PH; Hutter P; Hogervorst FB; Chong G; Foulkes WD
    Hum Mutat; 2006 Apr; 27(4):388. PubMed ID: 16541406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A common MSH2 mutation in English and North American HNPCC families: origin, phenotypic expression, and sex specific differences in colorectal cancer.
    Froggatt NJ; Green J; Brassett C; Evans DG; Bishop DT; Kolodner R; Maher ER
    J Med Genet; 1999 Feb; 36(2):97-102. PubMed ID: 10051005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Large genomic rearrangements and germline epimutations in Lynch syndrome.
    Gylling A; Ridanpää M; Vierimaa O; Aittomäki K; Avela K; Kääriäinen H; Laivuori H; Pöyhönen M; Sallinen SL; Wallgren-Pettersson C; Järvinen HJ; Mecklin JP; Peltomäki P
    Int J Cancer; 2009 May; 124(10):2333-40. PubMed ID: 19173287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The 5' region of the MSH2 gene involved in hereditary non-polyposis colorectal cancer contains a high density of recombinogenic sequences.
    Charbonnier F; Baert-Desurmont S; Liang P; Di Fiore F; Martin C; Frerot S; Olschwang S; Wang Q; Buisine MP; Gilbert B; Nilbert M; Lindblom A; Frebourg T
    Hum Mutat; 2005 Sep; 26(3):255-61. PubMed ID: 16086322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mismatch repair gene mutation spectrum in the Swedish Lynch syndrome population.
    Lagerstedt-Robinson K; Rohlin A; Aravidis C; Melin B; Nordling M; Stenmark-Askmalm M; Lindblom A; Nilbert M
    Oncol Rep; 2016 Nov; 36(5):2823-2835. PubMed ID: 27601186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hereditary nonpolyposis colorectal cancer: pitfalls in deletion screening in MSH2 and MLH1 genes.
    Wehner M; Mangold E; Sengteller M; Friedrichs N; Aretz S; Friedl W; Propping P; Pagenstecher C
    Eur J Hum Genet; 2005 Aug; 13(8):983-6. PubMed ID: 15870828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular analysis of hereditary nonpolyposis colorectal cancer in the United States: high mutation detection rate among clinically selected families and characterization of an American founder genomic deletion of the MSH2 gene.
    Wagner A; Barrows A; Wijnen JT; van der Klift H; Franken PF; Verkuijlen P; Nakagawa H; Geugien M; Jaghmohan-Changur S; Breukel C; Meijers-Heijboer H; Morreau H; van Puijenbroek M; Burn J; Coronel S; Kinarski Y; Okimoto R; Watson P; Lynch JF; de la Chapelle A; Lynch HT; Fodde R
    Am J Hum Genet; 2003 May; 72(5):1088-100. PubMed ID: 12658575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel germline mutation (300-305delAGTTGA) in the human MSH2 gene in hereditary non-polyposis colorectal cancer (HNPCC).
    Glasl S; Papatheodorou L; Baretton G; Jung C; Gross M
    Hum Mutat; 2000 Jul; 16(1):91-2. PubMed ID: 10874318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Presymptomatic diagnosis using a deletion of a single codon in families with hereditary non-polyposis colorectal cancer.
    Ripa RS; Katballe N; Wikman FP; Jäger AC; Bernstein I; Orntoft T; Schwartz M; Nielsen FC; Bisgaard ML
    Mutat Res; 2005 Feb; 570(1):89-96. PubMed ID: 15680406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New founding mutation in MSH2 associated with hereditary nonpolyposis colorectal cancer syndrome on the Island of Tenerife.
    Medina-Arana V; Barrios Y; Fernández-Peralta A; Herrera M; Chinea N; Lorenzo N; Jiménez A; Martín-López JV; González-Hermoso F; Salido E; González-Aguilera JJ
    Cancer Lett; 2006 Dec; 244(2):268-73. PubMed ID: 16500024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.